Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, I. P. Pavlova 6, 77900 Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 1333/5, 77900 Olomouc, Czech Republic.
Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 1333/5, 77900 Olomouc, Czech Republic.
Blood Cells Mol Dis. 2020 Mar;81:102380. doi: 10.1016/j.bcmd.2019.102380. Epub 2019 Nov 11.
Diamond-Blackfan anemia (DBA) is a rare congenital erythroid aplasia, underlied by haploinsufficient mutations in genes coding for ribosomal proteins (RP) in approximately 70% of cases. DBA is frequently associated with somatic malformations, endocrine dysfunction and with an increased predisposition to cancer. Here we present clinical and genetic characteristics of 62 patients from 52 families enrolled in the Czech and Slovak DBA Registry. Whole exome sequencing (WES) and array comparative genomic hybridization (aCGH) were employed to identify causative mutations in newly diagnosed patients and in cases with previously unrecognized molecular pathology. RP mutation detection rate was 81% (50/62 patients). This included 8 novel point mutations and 4 large deletions encompassing some of the RP genes. Malignant or predisposing condition developed in 8/62 patients (13%): myelodysplastic syndrome in 3 patients; breast cancer in 2 patients; colorectal cancer plus ocular tumor, diffuse large B-cell lymphoma and multiple myeloma each in one case. These patients exclusively harbored RPL5, RPL11 or RPS19 mutations. Array CGH is beneficial for detection of novel mutations in DBA due to its capacity to detect larger chromosomal aberrations. Despite the importance of genotype-phenotype correlation in DBA, phenotypic differences among family members harboring an identical mutation were observed.
Diamond-Blackfan 贫血(DBA)是一种罕见的先天性红细胞发育不全,约 70%的病例是由于核糖体蛋白(RP)基因编码的单等位基因突变引起的。DBA 常与躯体畸形、内分泌功能障碍和癌症易感性增加有关。本文介绍了捷克和斯洛伐克 DBA 登记处 52 个家系的 62 例患者的临床和遗传特征。对新诊断的患者和以前未发现分子病理学的患者进行了全外显子组测序(WES)和阵列比较基因组杂交(aCGH),以确定致病突变。RP 突变检测率为 81%(50/62 例)。这包括 8 个新的点突变和 4 个包含部分 RP 基因的大片段缺失。8/62 例患者(13%)发生恶性或易患疾病:3 例为骨髓增生异常综合征;2 例为乳腺癌;1 例为结直肠癌伴眼部肿瘤、弥漫性大 B 细胞淋巴瘤和多发性骨髓瘤。这些患者均携带 RPL5、RPL11 或 RPS19 突变。aCGH 有利于检测 DBA 中的新突变,因为它能够检测到更大的染色体异常。尽管 DBA 中的基因型-表型相关性很重要,但携带相同突变的家庭成员之间存在表型差异。